4,797 Shares in Becton, Dickinson and Company $BDX Acquired by Oak Thistle LLC

Oak Thistle LLC acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 4,797 shares of the medical instruments supplier’s stock, valued at approximately $898,000.

A number of other institutional investors have also recently modified their holdings of BDX. Saudi Central Bank bought a new position in shares of Becton, Dickinson and Company in the first quarter worth $26,000. Bell Investment Advisors Inc grew its stake in Becton, Dickinson and Company by 474.1% during the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 128 shares in the last quarter. Kelly Lawrence W & Associates Inc. CA acquired a new stake in Becton, Dickinson and Company during the first quarter worth about $31,000. Bank of Jackson Hole Trust increased its holdings in Becton, Dickinson and Company by 85.6% in the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after buying an additional 95 shares during the period. Finally, WPG Advisers LLC acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $36,000. 86.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on BDX shares. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Piper Sandler decreased their price target on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Royal Bank Of Canada boosted their price target on Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a report on Wednesday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus lowered their target price on Becton, Dickinson and Company from $224.00 to $210.00 in a research note on Friday, November 7th. Four research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and an average price target of $205.64.

Becton, Dickinson and Company Trading Down 0.2%

Shares of BDX stock opened at $194.91 on Friday. Becton, Dickinson and Company has a twelve month low of $162.29 and a twelve month high of $251.99. The stock’s fifty day simple moving average is $189.29 and its 200 day simple moving average is $185.16. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $55.63 billion, a P/E ratio of 33.43, a P/E/G ratio of 1.80 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The firm had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Monday, December 8th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s payout ratio is presently 72.04%.

Insider Activity at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the transaction, the director owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael David Garrison sold 629 shares of the business’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $196.03, for a total transaction of $123,302.87. Following the completion of the sale, the executive vice president directly owned 13,105 shares in the company, valued at approximately $2,568,973.15. This represents a 4.58% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 1,036 shares of company stock valued at $197,225. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.